WS
CYTO

Wedbush Securities’s Altamira Therapeutics Ltd CYTO Stock Holding History

Wedbush Securities’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-131
Closed -$49K – 1034
2020
Q2 		$49K Buy
+131
New +$49.2K ﹤0.01% 906
2020
Q1 		– Sell
-55
Closed -$36K – 1030
2019
Q4 		$36K Buy
+55
New +$37.3K ﹤0.01% 974
2019
Q3 		– Sell
-31
Closed -$35K – 1036
2019
Q2 		$35K Buy
31
+10
+48% +$17.4K ﹤0.01% 963
2019
Q1 		$59K Buy
+21
New +$67.5K 0.01% 888
2018
Q4 		– Sell
-19
Closed -$54K – 946
2018
Q3 		$54K Buy
19
+11
+138% +$29K 0.01% 869
2018
Q2 		$49K Buy
8
+5
+167% +$52.8K 0.01% 839
2018
Q1 		$33K Buy
3
+2
+200% +$53.6K ﹤0.01% 800
2017
Q4 		$26K Hold
1
– – ﹤0.01% 838
2017
Q3 		$36K Hold
1
– – ﹤0.01% 814
2017
Q2 		$32K Hold
1
– – ﹤0.01% 815
2017
Q1 		$41K Buy
+1
New +$80.2K 0.01% 810
2016
Q4 		– Hold
0
– – – 805
2016
Q3 		– Hold
0
– – – 806

Other funds holding CYTO

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wedbush Securities's CYTO Position: Q3 2020 in Review

Wedbush Securities sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2020, closing a stake of 131 shares — an estimated $49K sold.

Wedbush Securities first reported a position in CYTO in Q1 2017 and held it in 11 quarters. The position peaked at $59K in Q1 2019. 4 funds tracked by Wall St. Rank hold CYTO as of Q3 2020.

  • Wedbush Securities reported no remaining Altamira Therapeutics Ltd position as of Q3 2020 after selling out during the quarter.
  • Wedbush Securities sold 131 Altamira Therapeutics Ltd shares in Q3 2020, an estimated $49K.
  • Wedbush Securities first reported a position in Altamira Therapeutics Ltd in Q1 2017 and held it in 11 quarters.
  • Wedbush Securities's Altamira Therapeutics Ltd position peaked at $59K in Q1 2019.
  • 4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.